SEC Form 4 · accession 0001104659-15-077672
EPIRUS Biopharmaceuticals, Inc. · EPRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Aurentz Vincent
Officer — Chief Business Officer
Period of report
Nov 9, 2015
Accepted (ET)
Nov 10, 2015 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001135906
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1 | $5.21 | Nov 9, 2015 | A | 219,487 | A | — | Nov 9, 2025 | Common Stock | 219,487 | 219,487 | D |
Explanation of responses
- F125% of the shares subject to this option shall vest on the one year anniversary of the grant date and the remaining shares shall vest in substantially equal monthly installments over the next three (3) years, provided the Reporting Person remains continuously employed by the Issuer through each vesting date.